Orange Biomed Lands on Fortune Korea's Top 40 with Portable Diabetes Test
illi News/10310647

Trending...
SEATTLE, Aug. 21, 2025 ~ Orange Biomed, a leading developer in the healthcare industry, has recently gained international recognition for its revolutionary microfluidic technology. The company's innovative approach to chronic disease management has earned them a spot on Fortune Korea's "Top 40 Emerging South Korean Healthcare Innovations" list, solidifying their growing presence in the U.S. healthcare market.

At the core of Orange Biomed's success is their flagship product, the OBM rapid A1C. This pocket-sized device is the first of its kind to utilize microfluidic technology to measure glycated hemoglobin (A1C). Unlike traditional lab tests, this portable device offers a more accessible and accurate option for diabetes monitoring, particularly for patients who face barriers to regular testing.

The award panel responsible for selecting Orange Biomed for this prestigious recognition included U.S. medical experts and consulting firm BDMT Global. They were impressed by the company's ability to directly address unmet needs in the U.S. healthcare system. "The OBM rapid A1C could transform how diabetes patients monitor their condition by removing logistical and cost barriers associated with lab-based testing," stated evaluators.

More on illi News
In addition to their groundbreaking product development, Orange Biomed is also dedicated to making a positive impact beyond their technology. Through their "M.A.P. YOUR HEALTH" campaign, they have partnered with health and community groups in Chicago to raise awareness about chronic disease prevention and expand access to care.

CEO and co-president Yeaseul Park sees this recognition as validation of the company's commitment to global healthcare innovation. "Being named to the Top 40 is not only an honor but also proof that our technology can make a real impact in the U.S. healthcare system," Park stated. "Our focus is on building strong partnerships in the U.S. and turning these opportunities into tangible results in the healthcare system."

With over USD 7.5 million in funding and multiple innovation awards, Orange Biomed has presented their groundbreaking technology at major U.S. forums such as the American Diabetes Association's Innovation Hub and the Diabetes Technology Meeting (DTM). They have also engaged with professional communities through ADLM and ADCES. The company is currently preparing a 510(k) submission to the FDA for potential clearance of their product.

For more information on Orange Biomed and their innovative technology, please visit www.orangebiomed.com and follow them on LinkedIn, Instagram, Facebook, and Youtube. With their dedication to improving chronic disease management and accessibility in healthcare, Orange Biomed is sure to continue making waves in the industry.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on illi News